Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Phase 2
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 250 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function. Synovial fibroblasts play a key role in RA pathogenesis, with treatment-refractory patients demonstrating increased numbers of these cells. The goal of this study is to evaluate the safety and effectiveness of ABBV-2294 (a combination of ABBV-722 and upadacitinib) compared to each drug alone in treating moderately to severely active RA. The platform study will measure improvements in disease activity using the American College of Rheumatology (ACR) criteria, changes in disease activity scores, and quality of life measures.
ABBV-2294 is an investigational combination drug being developed for the treatment of moderately to severely active rheumatoid arthritis. This is a Phase 2b, randomized, double-blind platform study. In sub-study 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment consisting of either ABBV-722 alone, upadacitinib alone, or various doses of ABBV-722 combined with upadacitinib. Adult participants with a diagnosis of moderately to severely active rheumatoid arthritis who have failed at least 1 prior biologic disease-modifying antirheumatic drug (bDMARD) will be enrolled. Around 250 participants will be enrolled in the study at multiple sites worldwide.
Participants will receive oral tablet doses of ABBV-2294 (combination of ABBV-722 and upadacitinib), ABBV-722 alone, or upadacitinib alone. The study comprises a 24-week Double-Blind Phase (Period 1) followed by an optional 52-week Blinded Long Term Extension Phase (Period 2), for a total treatment duration of up to 76 weeks. After completing treatment, participants will have a 30-day Follow-Up Period.
Participants will attend regular visits during the study at a hospital or clinic, including screening, baseline, and scheduled visits through Week 76, followed by a follow-up visit. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Documented clinical diagnosis of RA for \>= 3 months and fulfills 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for Rheumatoid arthritis
- No clinically significant medical conditions that would interfere with study participation or compromise participant safety
- Willing and able to comply with procedures required in this Master Protocol and all actively enrolling substudies
- Female participants who are not pregnant or breastfeeding, with negative pregnancy tests at Screening and Baseline
Exclusion Criteria:
- Development of a major cardiovascular event (e.g., acute myocardial infarction, stroke) while on study treatment
- Serious infection (e.g., sepsis) which cannot be adequately controlled by anti-infective treatment
- Confirmed diagnosis of deep vein thrombosis, pulmonary embolus or arterial thrombosis
- Development of active tuberculosis at any time during the study
- Development of any malignancy except localized non-melanoma skin cancer or carcinoma in situ of the cervix
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- Triple masked
ABBV-2294 Dose A
Participants will receive co-administration of ABBV-722 and upadacitinib
Drug: ABBV-722 · Drug: Upadacitinib
ABBV-2294 Dose B
Participants will receive co-administration of ABBV-722 and upadacitinib
Drug: ABBV-722 · Drug: Upadacitinib
ABBV-2294 Dose C
Participants will receive co-administration of ABBV-722 and upadacitinib
Drug: ABBV-722 · Drug: Upadacitinib
ABBV-722 Monotherapy
Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib.
Drug: ABBV-722
Upadacitinib Monotherapy
Participants will receive upadacitinib.
Drug: Upadacitinib
ABBV-722 DRUG
Oral Tablet
Upadacitinib DRUG
Oral Tablet
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Percentage of Participants Achieving ACR50 Response
Time frame: Week 12
The ACR50 response is defined as at least 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis. The ACR50 response requires at least 50% improvement in tender and swollen joint counts and at least 50% improvement in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function (HAQ-DI), and acute phase reactant (CRP or ESR).
Number of Participants Experiencing Adverse Events
Time frame: Up to 80 Weeks
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Secondary measures
Percentage of Participants Achieving ACR20 Response
Time frame: Week 12
ACR20 response is defined as at least 20% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate).
Percentage of Participants Achieving ACR70 Response
Time frame: Week 12
ACR70 response is defined as at least 70% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate).
Percentage of Participants Achieving Low Disease Activity Based on DAS28 (CRP) <= 3.2
Time frame: Week 12
Low Disease Activity (LDA) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) of \<= 3.2. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity.
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) < 2.6
Time frame: Week 12
Clinical Remission (CR) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) of \< 2.6. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity.
Percentage of Participants with a Change From Baseline in DAS28 (CRP)
Time frame: Baseline to Week 12
Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. A negative change from Baseline indicates improvement.
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) <= 10
Time frame: Week 12
Low Disease Activity (LDA) is defined as a Clinical Disease Activity Index (CDAI) of \<= 10. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity.
Percentage of Participants Achieving Clinical Remission Based on CDAI <= 2.8
Time frame: Week 12
Clinical Remission (CR) is defined as a Clinical Disease Activity Index (CDAI) of \<= 2.8. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (0)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
No locations are listed. Use the official study contact.
Study team and timeline
- Lead sponsor
- AbbVie
- Study start
- Dec 7, 2026 Estimated
- Primary completion
- 2029-07 Estimated
- Study completion
- 2029-07 Estimated
- First posted
- Oct 29, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026